Krystal: EMA OKs Application for VYJUVEK for Treatment of Dystrophic Epidermolysis Bullosa

 

• If approved, ~3,000 people with DEB in the European Union could receive VYJUVEK to treat the underlying cause of the disease for the first time
   
• VYJUVEK received Orphan Drug Designation and PRIME designation from the EMA

https://www.biospace.com/article/releases/krystal-biotech-announces-ema-validation-of-marketing-authorization-application-for-vyjuvek-for-the-treatment-of-dystrophic-epidermolysis-bullosa/